

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

CYP4F12 RABBIT PAB

货号: S218564

产品全名: CYP4F12 兔多抗 基因符号 CYPIVF12; F22329_1

UNIPROT ID: Q9HCS2 (Gene Accession - BC035350)

背景: This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein likely localizes to the endoplasmic reticulum. When expressed in yeast the enzyme is capable of oxdizing arachidonic acid. It can also catalyze the epoxidation of 22:6n-3 and 22:5n-3 polyunsaturated long-chain fatty acids. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Alternative splicing results in multiple transcript variants.

抗原: Fusion protein of human CYP4F12

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 20-100; ELISA: 5000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Cardiovascular, Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human gastric cancer tissue using 218564(CYP4F12 Antibody) at a dilution of Human gastric cancer tissue is first treated with the fusion protein 1/30(Cytoplasm and Cell membrane)



In comparision with the IHC on the left, the same paraffin-embedded and then with 218564(Anti-CYP4F12 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffinembedded Human liver cancer tissue using 218564(Anti-CYP4F12 Antibody) at a dilution of 1/30.



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with fusion protein and then with D224710 (Anti-CYP4F12 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010